[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiu_OYCB1ihvSHc9XnU8fO8OlZS4LkOjmsrbvjbwskc8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Erasmus Medical Center",[4],465,false,178,39,381866,49,341,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Coronary Artery Disease",11,{"name":18,"count":19},"Anxiety",9,{"name":21,"count":22},"Quality of Life",8,{"name":24,"count":25},"Aortic Valve Stenosis",7,{"name":27,"count":28},"Depression",6,{"name":30,"count":28},"Heart Failure",{"name":32,"count":28},"Hypertension",{"name":34,"count":28},"Glioblastoma",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04707326","Defining the Potency of DTG\u002F3TC for Suppressed HIV Patients in Real-life: the DUALING Study","2023-11-01","Dolutegravir \u002F Lamivudine Pill",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04094038","The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients","2024-04-02","Olimel N12",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04314193","Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis","2024-08-13","Methotrexate",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04729543","MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer","2024-12-20","Adoptive therapy with autologous MC2 TCR T cells",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05600127","Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer","2025-04","Avelumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04191460","Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer","2025-05-01","cRGD-ZW800-1.",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05552287","Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease","2025-08","Infliximab",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05964114","First Time Right of Vancomycin","2025-10","Vancomycin",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06498037","Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.","2025-11-01","Fentanyl",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06193525","FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test","2025-12","Talazoparib",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,176,204,226,251,269,295,313,340,368,396,425,443,461,519,550,568,586,604,631,649,676,701,751,791,820,849,876,899,917,941,961,987,1010,1035,1061,1079,1101,1127,1152,1178,1200,1224,1254,1280,1301,1327,1355,1373,1398,1420,1454,1482,1500,1526,1544,1571,1589,1616,1634,1659,1677,1704,1722,1748,1772,1798,1816,1843,1869,1887,1905,1932,1950,1968,1993,2018,2036,2061,2089,2107,2125,2143,2161,2186,2210,2236,2254,2279,2311,2348,2373,2398,2422,2440,2464,2489,2517,2542,2566,2593,2611,2636,2660,2684,2708,2733,2751,2777,2807,2832,2850,2873,2910,2934,2958,2983,3007,3031,3056,3081,3107,3125,3148,3175,3193,3218,3236,3254,3272,3295,3323,3347,3372,3399,3417,3445,3468,3497,3515,3533,3551,3575,3601,3619,3644,3672,3690,3712,3736,3762,3780,3798,3816,3844,3862,3880,3906,3931,3949,3976,3994,4012,4030,4055],{"intervention":50,"totalTrials":95,"cells":96},5,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":135},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":134,"soonestReadout":49},[108,118],{"nctId":47,"briefTitle":48,"status":109,"phases":110,"primaryCompletion":49,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"ACTIVE_NOT_RECRUITING",[91],"2026-07","2020-06-01",138,[115],"Sarcoidosis, Pulmonary",[50,117],"Prednisone",{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":123,"start":79,"enrollment":124,"conditions":125,"interventions":132},"NCT07381556","Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study","RECRUITING",[91],"2027-11-01",50,[126,127,128,129,130,131],"Alopecia Areata(AA)","Alopecia Areata (AA)","Alopecia Totalis\u002FUniversalis","Alopecia Universalis (AU)","Alopecia Totalis (AT)","Alopecia Areata (& Ophiasis)",[50,133],"Cyclosporin",2,{"trials":136,"activeCount":134,"soonestReadout":154},[137,150,160],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":124,"conditions":145,"interventions":148},"NCT07190534","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","NOT_YET_RECRUITING",[],"2026-11","2027-05","2025-11",[146,147],"Frontal Fibrosing Alopecia","Cicatricial Alopecia",[149,50],"Hydroxychloroquine",{"nctId":151,"briefTitle":152,"status":121,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT06512753","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial",[],"2026-07-01","2024-07-01",56,[158,147],"Lichen Planopilaris",[149,50],{"nctId":161,"briefTitle":162,"status":163,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":173},"NCT06512766","a Retrospective Study on the Systemic Treatment of LPP and FFA","COMPLETED",[],"2023-02-01","2022-09-23",315,[147,158,169,146,170,171,172],"Lichen Plano-Pilaris","Hair Diseases","Scarring Alopecia","Hair Loss\u002FBaldness",[149,50,174,175],"Cyclosporine A","Retinoids",{"intervention":177,"totalTrials":178,"cells":179},"Gardasil 9 Suspension for",1,{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":202},{"trials":181,"activeCount":99},[],{"trials":183,"activeCount":99},[],{"trials":185,"activeCount":99},[],{"trials":187,"activeCount":99},[],{"trials":189,"activeCount":178,"soonestReadout":194},[190],{"nctId":191,"briefTitle":192,"status":140,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":201},"NCT06052696","Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL",[91],"2028-12-01","2030-12-01","2023-12-01",500,[199,200],"Vulvar HSIL","HPV",[177],{"trials":203,"activeCount":99},[],{"intervention":80,"totalTrials":178,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":224},{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":178,"soonestReadout":79},[216],{"nctId":77,"briefTitle":78,"status":121,"phases":217,"primaryCompletion":79,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},[91],"2025-12-02","2024-02-23",45,[222],"Cancer Pain",[80],{"trials":225,"activeCount":99},[],{"intervention":45,"totalTrials":178,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":249},{"trials":229,"activeCount":99},[],{"trials":231,"activeCount":99},[],{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":178,"soonestReadout":44},[238],{"nctId":42,"briefTitle":43,"status":109,"phases":239,"primaryCompletion":44,"completion":111,"start":240,"enrollment":241,"conditions":242,"interventions":247},[91],"2019-09-16",166,[243,244,245,246],"End Stage Renal Disease","Malnutrition","Sarcopenia","Hemodialysis Complication",[45,248],"Glucose IV",{"trials":250,"activeCount":99},[],{"intervention":248,"totalTrials":178,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":178,"soonestReadout":44},[263],{"nctId":42,"briefTitle":43,"status":109,"phases":264,"primaryCompletion":44,"completion":111,"start":240,"enrollment":241,"conditions":265,"interventions":266},[91],[243,244,245,246],[45,248],{"trials":268,"activeCount":99},[],{"intervention":270,"totalTrials":178,"cells":271},"Dexamethasone",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":293},{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":178,"soonestReadout":286},[282],{"nctId":283,"briefTitle":284,"status":121,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":197,"conditions":289,"interventions":291},"NCT06118710","Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment",[91],"2027-06-01","2027-08-01","2024-06-25",[290],"Cancer",[270,292],"H1 Antihistaminics",{"trials":294,"activeCount":99},[],{"intervention":292,"totalTrials":178,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":311},{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":99},[],{"trials":304,"activeCount":99},[],{"trials":306,"activeCount":178,"soonestReadout":286},[307],{"nctId":283,"briefTitle":284,"status":121,"phases":308,"primaryCompletion":286,"completion":287,"start":288,"enrollment":197,"conditions":309,"interventions":310},[91],[290],[270,292],{"trials":312,"activeCount":99},[],{"intervention":314,"totalTrials":178,"cells":315},"Intravenous ferric carboxymaltose",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":338},{"trials":317,"activeCount":99},[],{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":178,"soonestReadout":330},[326],{"nctId":327,"briefTitle":328,"status":121,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":337},"NCT07370688","Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation",[91],"2028-07","2024-08-12",402,[24,334,335,336],"Iron Deficiency","TAVI(Transcatheter Aortic Valve Implantation)","Cardiovascular Diseases",[314],{"trials":339,"activeCount":99},[],{"intervention":341,"totalTrials":178,"cells":342},"Atorvastatin",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":366},{"trials":344,"activeCount":99},[],{"trials":346,"activeCount":99},[],{"trials":348,"activeCount":99},[],{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":178,"soonestReadout":357},[353],{"nctId":354,"briefTitle":355,"status":140,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":365},"NCT06785974","Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis",[91],"2027-02","2030-02","2025-02",140,[362,363,364],"Atherosclerosis","Melanoma","Immune-related Adverse Event",[341],{"trials":367,"activeCount":99},[],{"intervention":369,"totalTrials":178,"cells":370},"Double dosing of beta-lactam antibiotic",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":394},{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":99},[],{"trials":378,"activeCount":99},[],{"trials":380,"activeCount":178,"soonestReadout":385},[381],{"nctId":382,"briefTitle":383,"status":121,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":393},"NCT06766461","Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis",[91],"2026-12-01","2027-12-01","2025-01-03",980,[390,391,392],"Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis","Septic Shock",[369],{"trials":395,"activeCount":99},[],{"intervention":397,"totalTrials":178,"cells":398},"Algucosidase alfa 20 mg\u002Fkg once every 4 weeks instead of once every 2 weeks",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":423},{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":178,"soonestReadout":413},[409],{"nctId":410,"briefTitle":411,"status":140,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":422},"NCT06575829","Treatment Frequency Reduction in Pompe Disease",[91],"2026-12-31","2027-12-31","2024-10-01",10,[418,419,420,421],"Pompe Disease (Late-onset)","GAA Deficiency","Glycogen Storage Disease Type II","Acid Maltase Deficiency",[397],{"trials":424,"activeCount":99},[],{"intervention":117,"totalTrials":178,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":441},{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":99},[],{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":178,"soonestReadout":49},[437],{"nctId":47,"briefTitle":48,"status":109,"phases":438,"primaryCompletion":49,"completion":111,"start":112,"enrollment":113,"conditions":439,"interventions":440},[91],[115],[50,117],{"trials":442,"activeCount":99},[],{"intervention":133,"totalTrials":178,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":459},{"trials":446,"activeCount":99},[],{"trials":448,"activeCount":99},[],{"trials":450,"activeCount":99},[],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":178,"soonestReadout":123},[455],{"nctId":119,"briefTitle":120,"status":121,"phases":456,"primaryCompletion":123,"completion":123,"start":79,"enrollment":124,"conditions":457,"interventions":458},[91],[126,127,128,129,130,131],[50,133],{"trials":460,"activeCount":99},[],{"intervention":70,"totalTrials":462,"cells":463},4,{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":506},{"trials":465,"activeCount":99},[],{"trials":467,"activeCount":99},[],{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":178,"soonestReadout":69},[474,487,498],{"nctId":475,"briefTitle":476,"status":477,"phases":478,"primaryCompletion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT01880307","Infliximab Top-down in Pediatric Crohn","TERMINATED",[91],"2014-12","2013-01",13,[483],"Crohn's Disease",[485,70,486],"Azathioprine","Prednisolon",{"nctId":488,"briefTitle":489,"status":163,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT02517684","Top-down Infliximab Study in Kids With Crohn's Disease",[91],"2019-12","2024-01","2015-04",100,[483],[70,497,485],"Prednisolone",{"nctId":67,"briefTitle":68,"status":121,"phases":499,"primaryCompletion":69,"completion":69,"start":500,"enrollment":124,"conditions":501,"interventions":505},[91],"2023-08-02",[502,503,504],"Crohn Disease","Child, Only","Biologic; Inadequate",[70],{"trials":507,"activeCount":99},[508],{"nctId":509,"briefTitle":510,"status":163,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":220,"conditions":515,"interventions":517},"NCT01971970","Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)",[],"2016-10-30","2017-01-30","2013-10",[516],"Inflammatory Bowel Diseases",[70,518],"Adalimumab",{"intervention":520,"totalTrials":178,"cells":521},"Leucovorin Calcium",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":546,"NA":548},{"trials":523,"activeCount":99},[],{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":178,"soonestReadout":534},[530],{"nctId":531,"briefTitle":532,"status":109,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":542},"NCT04927780","Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer",[90],"2027-01","2029-07","2021-09-07",378,[539,540,541],"Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Adenocarcinoma",[520,543,544,545],"Fluorouracil","Irinotecan Hydrochloride","Oxaliplatin",{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"intervention":543,"totalTrials":178,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":564,"NA":566},{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":178,"soonestReadout":534},[560],{"nctId":531,"briefTitle":532,"status":109,"phases":561,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":562,"interventions":563},[90],[539,540,541],[520,543,544,545],{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"intervention":544,"totalTrials":178,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":582,"NA":584},{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":178,"soonestReadout":534},[578],{"nctId":531,"briefTitle":532,"status":109,"phases":579,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":580,"interventions":581},[90],[539,540,541],[520,543,544,545],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"intervention":545,"totalTrials":178,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":600,"NA":602},{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":178,"soonestReadout":534},[596],{"nctId":531,"briefTitle":532,"status":109,"phases":597,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":598,"interventions":599},[90],[539,540,541],[520,543,544,545],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"intervention":605,"totalTrials":178,"cells":606},"Atropine Ophthalmic 0.05%",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":627,"NA":629},{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":178,"soonestReadout":619},[615],{"nctId":616,"briefTitle":617,"status":121,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT05667454","MAD Trial: Myopia Atropine Dose",[90],"2029-03-01","2029-04-01","2022-12-19",550,[624],"Progressive Myopia",[605,626],"Atropine Ophthalmic 0.5%",{"trials":628,"activeCount":99},[],{"trials":630,"activeCount":99},[],{"intervention":626,"totalTrials":178,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":645,"NA":647},{"trials":634,"activeCount":99},[],{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":178,"soonestReadout":619},[641],{"nctId":616,"briefTitle":617,"status":121,"phases":642,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":643,"interventions":644},[90],[624],[605,626],{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[],{"intervention":650,"totalTrials":178,"cells":651},"Doxapram",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":672,"NA":674},{"trials":653,"activeCount":99},[],{"trials":655,"activeCount":99},[],{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":178,"soonestReadout":664},[660],{"nctId":661,"briefTitle":662,"status":121,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":671},"NCT04430790","Doxapram Therapy in Preterm Infants (DOXA Trial)",[90],"2026-05-01","2034-05-01","2020-06-15",396,[669,670],"Apnea of Prematurity","Respiratory Insufficiency",[650],{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":99},[],{"intervention":677,"totalTrials":178,"cells":678},"Adjuvant chemotherapy",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":697,"NA":699},{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[],{"trials":686,"activeCount":178,"soonestReadout":691},[687],{"nctId":688,"briefTitle":689,"status":140,"phases":690,"primaryCompletion":691,"completion":692,"start":74,"enrollment":693,"conditions":694,"interventions":696},"NCT07188025","ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer",[90],"2030-10","2035-10",103,[695],"Rectal Cancer",[677],{"trials":698,"activeCount":99},[],{"trials":700,"activeCount":99},[],{"intervention":702,"totalTrials":703,"cells":704},"Nivolumab",3,{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":721,"PHASE4":723,"NA":735},{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":178,"soonestReadout":715},[711],{"nctId":712,"briefTitle":713,"status":109,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT05491616","Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study",[89],"2026-10","2022-09-29",77,[719],"Esophageal Cancer",[702],{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":99},[725],{"nctId":726,"briefTitle":727,"status":728,"phases":729,"primaryCompletion":415,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT06116461","Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response","UNKNOWN",[91],"2025-01","2022-01-05",34,[363],[702],{"trials":736,"activeCount":178,"soonestReadout":741},[737],{"nctId":738,"briefTitle":739,"status":121,"phases":740,"primaryCompletion":741,"completion":742,"start":165,"enrollment":743,"conditions":744,"interventions":749},"NCT05652673","Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial",[92],"2025-12-01","2029-12-01",80,[745,746,747,748],"Melanoma Stage IV","Melanoma Stage III","Immunotherapy","Toxicity, Drug",[750],"nivolumab",{"intervention":752,"totalTrials":134,"cells":753},"Topiramate",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":755,"activeCount":99},[],{"trials":757,"activeCount":99},[],{"trials":759,"activeCount":178,"soonestReadout":776},[760,772],{"nctId":761,"briefTitle":762,"status":728,"phases":763,"primaryCompletion":59,"completion":69,"start":764,"enrollment":765,"conditions":766,"interventions":771},"NCT06282783","Studying Topiramate for Re-Activating the HIV-1 Reservoir",[88,89],"2024-09",12,[767,768,769,770],"HIV-1-infection","Hiv","HIV Infections","HIV I Infection",[752],{"nctId":773,"briefTitle":774,"status":140,"phases":775,"primaryCompletion":776,"completion":330,"start":777,"enrollment":778,"conditions":779,"interventions":782},"NCT07384624","Combining Latency Reversing Agents to Address the HIV Reservoir",[88,89],"2028-06","2026-04",30,[780,781],"HIV (Human Immunodeficiency Virus)","HIV -1 Infection",[783,784,752],"Pyrimethamine","Lenalidomide",{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":99},[],{"intervention":783,"totalTrials":134,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":99},[],{"trials":798,"activeCount":178,"soonestReadout":776},[799,803],{"nctId":773,"briefTitle":774,"status":140,"phases":800,"primaryCompletion":776,"completion":330,"start":777,"enrollment":778,"conditions":801,"interventions":802},[88,89],[780,781],[783,784,752],{"nctId":804,"briefTitle":805,"status":163,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT03525730","LRAs United as a Novel Anti-HIV Strategy.",[88,89],"2019-07-25","2020-10-01","2018-04-18",28,[767],[813,783],"Valproic Acid",{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"intervention":821,"totalTrials":178,"cells":822},"Hepatic Arterial Infusion Pump chemotherapy with floxuridin",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":178,"soonestReadout":833},[829],{"nctId":830,"briefTitle":831,"status":121,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":842},"NCT06888063","Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery",[89],"2026-09","2031-09","2024-11-20",40,[838,839,840,841],"Intrahepatic Bile Duct Cancer","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Bile Duct Carcinoma","Intrahepatic Cholangiocarcinoma",[821],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"intervention":850,"totalTrials":178,"cells":851},"CRGD-ZW800-1",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":178,"soonestReadout":862},[858],{"nctId":859,"briefTitle":860,"status":140,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":869},"NCT05752149","Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial",[89],"2027-02-01","2027-03-01","2025-06-01",27,[867,868],"Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Hypopharynx",[850],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"intervention":55,"totalTrials":178,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":99},[],{"trials":883,"activeCount":178,"soonestReadout":54},[884],{"nctId":52,"briefTitle":53,"status":121,"phases":885,"primaryCompletion":54,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":892},[88,89],"2027-10-20","2020-10-20",20,[363,890,891],"Melanoma, Uveal","Head and Neck Cancer",[55],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"intervention":784,"totalTrials":178,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":902,"activeCount":99},[],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":178,"soonestReadout":776},[907],{"nctId":773,"briefTitle":774,"status":140,"phases":908,"primaryCompletion":776,"completion":330,"start":777,"enrollment":778,"conditions":909,"interventions":910},[88,89],[780,781],[783,784,752],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"intervention":918,"totalTrials":178,"cells":919},"Esmolol",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":921,"activeCount":99},[],{"trials":923,"activeCount":99},[],{"trials":925,"activeCount":178,"soonestReadout":741},[926],{"nctId":927,"briefTitle":928,"status":121,"phases":929,"primaryCompletion":741,"completion":930,"start":931,"enrollment":888,"conditions":932,"interventions":934},"NCT06522594","REMAP ECMO - Beta Receptor Modulation Trial",[89],"2025-12-03","2024-06-01",[30,933],"Cardiogenic Shock",[918],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"intervention":85,"totalTrials":178,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":178,"soonestReadout":84},[949],{"nctId":82,"briefTitle":83,"status":121,"phases":950,"primaryCompletion":84,"completion":84,"start":240,"enrollment":951,"conditions":952,"interventions":954},[89],66,[953],"Advanced Breast Cancer",[85],{"trials":956,"activeCount":99},[],{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":99},[],{"intervention":962,"totalTrials":178,"cells":963},"intraperitoneal chemotherapy",{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":965,"activeCount":99},[],{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":178,"soonestReadout":974},[970],{"nctId":971,"briefTitle":972,"status":121,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":980},"NCT07133490","INTERACT Stomach-II",[89],"2027-10-01","2028-07-01","2025-10-01",55,[979],"Peritoneal Metastases From Gastric Cancer",[962],{"trials":982,"activeCount":99},[],{"trials":984,"activeCount":99},[],{"trials":986,"activeCount":99},[],{"intervention":65,"totalTrials":178,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":178,"soonestReadout":64},[995],{"nctId":62,"briefTitle":63,"status":121,"phases":996,"primaryCompletion":64,"completion":997,"start":998,"enrollment":810,"conditions":999,"interventions":1003},[89],"2025-07-01","2022-07-12",[1000,1001,1002],"Squamous Cell Carcinoma of the Head and Neck","Oral Cancer","Squamous Cell Carcinoma of the Oral Cavity",[65],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"intervention":1011,"totalTrials":178,"cells":1012},"FLOT-CROSS or CROSS-FLOT",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1029,"PHASE4":1031,"NA":1033},{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":99},[],{"trials":1018,"activeCount":178,"soonestReadout":1023},[1019],{"nctId":1020,"briefTitle":1021,"status":121,"phases":1022,"primaryCompletion":1023,"completion":742,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT06161818","Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction",[89],"2029-09-01","2025-09-12",216,[719,1027],"Adenocarcinoma of the Esophagus",[1011],{"trials":1030,"activeCount":99},[],{"trials":1032,"activeCount":99},[],{"trials":1034,"activeCount":99},[],{"intervention":1036,"totalTrials":178,"cells":1037},"Darolutamide",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":178,"soonestReadout":143},[1044],{"nctId":1045,"briefTitle":1046,"status":121,"phases":1047,"primaryCompletion":143,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1053},"NCT05762536","Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC",[89],"2028-05","2023-11-29",245,[1052],"Metastatic Castration-resistant Prostate Cancer",[1036,1054],"Docetaxel or cabazitaxel",{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"intervention":1054,"totalTrials":178,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":1064,"activeCount":99},[],{"trials":1066,"activeCount":99},[],{"trials":1068,"activeCount":178,"soonestReadout":143},[1069],{"nctId":1045,"briefTitle":1046,"status":121,"phases":1070,"primaryCompletion":143,"completion":1048,"start":1049,"enrollment":1050,"conditions":1071,"interventions":1072},[89],[1052],[1036,1054],{"trials":1074,"activeCount":99},[],{"trials":1076,"activeCount":99},[],{"trials":1078,"activeCount":99},[],{"intervention":60,"totalTrials":178,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":178,"soonestReadout":59},[1087],{"nctId":57,"briefTitle":58,"status":121,"phases":1088,"primaryCompletion":59,"completion":1089,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},[89],"2026-12","2022-12-01",64,[1093],"Urothelial Carcinoma",[60],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":99},[],{"intervention":1102,"totalTrials":178,"cells":1103},"olaparib",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1119,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":178,"soonestReadout":1112},[1108],{"nctId":1109,"briefTitle":1110,"status":121,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1118},"NCT05870423","Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors",[88],"2027-01-01","2022-06-01",24,[1116,1117],"Neuroendocrine Tumors","Peptide Receptor Radionuclide Therapy",[1102],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"intervention":1128,"totalTrials":178,"cells":1129},"Mesopher",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":178,"soonestReadout":1138},[1134],{"nctId":1135,"briefTitle":1136,"status":121,"phases":1137,"primaryCompletion":1138,"completion":413,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1143},"NCT05304208","dENdritic Cell Therapy Combined With SURgEry in Mesothelioma",[88],"2025-12-31","2021-11-02",16,[1142],"Mesotheliomas Pleural",[1128],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"intervention":149,"totalTrials":703,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":134,"soonestReadout":154},[1166,1170,1174],{"nctId":138,"briefTitle":139,"status":140,"phases":1167,"primaryCompletion":142,"completion":143,"start":144,"enrollment":124,"conditions":1168,"interventions":1169},[],[146,147],[149,50],{"nctId":151,"briefTitle":152,"status":121,"phases":1171,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":1172,"interventions":1173},[],[158,147],[149,50],{"nctId":161,"briefTitle":162,"status":163,"phases":1175,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":1176,"interventions":1177},[],[147,158,169,146,170,171,172],[149,50,174,175],{"intervention":75,"totalTrials":178,"cells":1179},{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":178,"soonestReadout":74},[1192],{"nctId":72,"briefTitle":73,"status":140,"phases":1193,"primaryCompletion":74,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},[92],"2026-06","2023-10",134,[75,1198],"Pharmacokinetics",[75],{"intervention":1201,"totalTrials":178,"cells":1202},"Topical application of a fluorescent imaging agent",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[],{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":178,"soonestReadout":386},[1215],{"nctId":1216,"briefTitle":1217,"status":121,"phases":1218,"primaryCompletion":386,"completion":386,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1223},"NCT06292845","Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents",[92],"2024-01-16",200,[1222],"Solid Tumor, Adult",[1201],{"intervention":1225,"totalTrials":178,"cells":1226},"Virtual Ward",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":99},[],{"trials":1232,"activeCount":99},[],{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[],{"trials":1238,"activeCount":178,"soonestReadout":1243},[1239],{"nctId":1240,"briefTitle":1241,"status":121,"phases":1242,"primaryCompletion":1243,"completion":1244,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1253},"NCT06936891","Virtual Ward for Early Discharge in Patients Receiving Inpatient Care",[92],"2028-10-16","2028-12-31","2025-04-16",306,[1248,1249,1250,1251,1252],"Early Discharge","Telemedicine","Virtual Clinic","Hospital at Home","Feasibility Studies",[1225],{"intervention":1255,"totalTrials":178,"cells":1256},"Blood sampling for pharmacokinetics",{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[],{"trials":1262,"activeCount":99},[],{"trials":1264,"activeCount":99},[],{"trials":1266,"activeCount":99},[],{"trials":1268,"activeCount":178,"soonestReadout":1089},[1269],{"nctId":1270,"briefTitle":1271,"status":121,"phases":1272,"primaryCompletion":1089,"completion":1273,"start":1274,"enrollment":951,"conditions":1275,"interventions":1279},"NCT07114627","Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients",[],"2027-06","2025-02-18",[1276,1277,719,1278],"Solid Cancer","Gastric (Cardia, Body) Cancer","Colorectal Cancer (CRC)",[1255],{"intervention":40,"totalTrials":178,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":99},[],{"trials":1287,"activeCount":99},[],{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":178,"soonestReadout":39},[1294],{"nctId":37,"briefTitle":38,"status":109,"phases":1295,"primaryCompletion":39,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1300},[],"2026-11-01","2019-11-01",2040,[768],[40],{"intervention":1302,"totalTrials":178,"cells":1303},"Home monitoring care",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":178,"soonestReadout":1320},[1316],{"nctId":1317,"briefTitle":1318,"status":121,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1326},"NCT06883448","Implementation of Home Monitoring in Patients With Pulmonary Fibrosis",[92],"2027-09-01","2024-10-02",220,[1324,1325],"Pulmonary Fibrosis","Interstitial Lung Disease (ILD)",[1302],{"intervention":1328,"totalTrials":178,"cells":1329},"S-ketamine infusion inpatient setting",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1340},{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":178,"soonestReadout":1347},[1342],{"nctId":1343,"briefTitle":1344,"status":1345,"phases":1346,"primaryCompletion":1347,"completion":974,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1353},"NCT05212571","Long-term Pain Modulation by Intravenous Esketamine in CRPS","ENROLLING_BY_INVITATION",[92],"2026-10-01","2022-04-19",60,[1351,1352],"Complex Regional Pain Syndromes","CRPS (Complex Regional Pain Syndromes)",[1328,1354],"S-ketamine infusion outpatient setting",{"intervention":1354,"totalTrials":178,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":178,"soonestReadout":1347},[1369],{"nctId":1343,"briefTitle":1344,"status":1345,"phases":1370,"primaryCompletion":1347,"completion":974,"start":1348,"enrollment":1349,"conditions":1371,"interventions":1372},[92],[1351,1352],[1328,1354],{"intervention":1374,"totalTrials":178,"cells":1375},"⁶⁸Ga-FAPI-46",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":178,"soonestReadout":1392},[1388],{"nctId":1389,"briefTitle":1390,"status":140,"phases":1391,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1140,"conditions":1394,"interventions":1397},"NCT06957782","The Value of 68Ga-FAPI PET\u002FCT for Evaluating Peritoneal Treatment Response",[92],"2027-03","2025-09",[1395,1396],"Peritoneal Metastasis","FAPI",[1374],{"intervention":485,"totalTrials":134,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1418},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[1410,1414],{"nctId":475,"briefTitle":476,"status":477,"phases":1411,"primaryCompletion":479,"start":480,"enrollment":481,"conditions":1412,"interventions":1413},[91],[483],[485,70,486],{"nctId":488,"briefTitle":489,"status":163,"phases":1415,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":1416,"interventions":1417},[91],[483],[70,497,485],{"trials":1419,"activeCount":99},[],{"intervention":1421,"totalTrials":134,"cells":1422},"Pegvisomant",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1452},{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[1433,1442],{"nctId":1434,"briefTitle":1435,"status":163,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":888,"conditions":1439,"interventions":1441},"NCT00642720","Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant\u002FPlacebo in Controlled Acromegalic Patients",[91],"2007-07","2006-10",[21,1440],"Acromegaly",[1421],{"nctId":1443,"briefTitle":1444,"status":728,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1349,"conditions":1449,"interventions":1450},"NCT02668172","Pasireotide LAR and Pegvisomant Study in Acromegaly",[91],"2017-03","2017-06","2015-08",[1440],[1451,1421],"Pasireotide LAR 60 mg",{"trials":1453,"activeCount":99},[],{"intervention":1455,"totalTrials":178,"cells":1456},"Midazolam",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1480},{"trials":1458,"activeCount":99},[],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[1467],{"nctId":1468,"briefTitle":1469,"status":163,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1478},"NCT01993459","The Effects of Midazolam on the Quality of Postoperative Recovery",[91],"2015-10","2014-02",192,[1475,18,1476,27,1477],"Postoperative Period","Fatigue","Aggression",[1455,1479],"NaCl (sodium chloride) 0,9%",{"trials":1481,"activeCount":99},[],{"intervention":1479,"totalTrials":178,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1498},{"trials":1485,"activeCount":99},[],{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[1494],{"nctId":1468,"briefTitle":1469,"status":163,"phases":1495,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":1473,"conditions":1496,"interventions":1497},[91],[1475,18,1476,27,1477],[1455,1479],{"trials":1499,"activeCount":99},[],{"intervention":1501,"totalTrials":178,"cells":1502},"Mycophenolate Mofetil",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1524},{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[1513],{"nctId":1514,"briefTitle":1515,"status":163,"phases":1516,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1523},"NCT00166244","Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation",[91],"2005-03","2006-04","2003-05",901,[1522],"De Novo Renal Transplant Recipient.",[1501],{"trials":1525,"activeCount":99},[],{"intervention":486,"totalTrials":178,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1542},{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[1538],{"nctId":475,"briefTitle":476,"status":477,"phases":1539,"primaryCompletion":479,"start":480,"enrollment":481,"conditions":1540,"interventions":1541},[91],[483],[485,70,486],{"trials":1543,"activeCount":99},[],{"intervention":1545,"totalTrials":178,"cells":1546},"tenofovir alafenamide",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1569},{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[1557],{"nctId":1558,"briefTitle":1559,"status":728,"phases":1560,"primaryCompletion":1561,"completion":1562,"start":1563,"enrollment":743,"conditions":1564,"interventions":1567},"NCT02957864","Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide",[91],"2020-06","2020-09","2016-10",[1565,768,1566],"Renal Insufficiency,Chronic","Therapeutic Agent Toxicity",[1545,1568],"abacavir",{"trials":1570,"activeCount":99},[],{"intervention":1568,"totalTrials":178,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1581,"NA":1587},{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":99},[],{"trials":1582,"activeCount":99},[1583],{"nctId":1558,"briefTitle":1559,"status":728,"phases":1584,"primaryCompletion":1561,"completion":1562,"start":1563,"enrollment":743,"conditions":1585,"interventions":1586},[91],[1565,768,1566],[1545,1568],{"trials":1588,"activeCount":99},[],{"intervention":1590,"totalTrials":178,"cells":1591},"HVIGI",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1600,"NA":1614},{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[],{"trials":1601,"activeCount":99},[1602],{"nctId":1603,"briefTitle":1604,"status":163,"phases":1605,"primaryCompletion":1606,"completion":1606,"start":1607,"enrollment":743,"conditions":1608,"interventions":1612},"NCT02996409","High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy",[91],"2019-07","2016-12",[1609,1610,1611],"Tendinopathy","Achilles Tendon Pain","Injection Site Fibrosis",[1590,1613],"LVIGI",{"trials":1615,"activeCount":99},[],{"intervention":1613,"totalTrials":178,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1624,"PHASE4":1626,"NA":1632},{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[1628],{"nctId":1603,"briefTitle":1604,"status":163,"phases":1629,"primaryCompletion":1606,"completion":1606,"start":1607,"enrollment":743,"conditions":1630,"interventions":1631},[91],[1609,1610,1611],[1590,1613],{"trials":1633,"activeCount":99},[],{"intervention":1635,"totalTrials":178,"cells":1636},"Amiloride",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1643,"PHASE4":1645,"NA":1657},{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[1647],{"nctId":1648,"briefTitle":1649,"status":163,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":810,"conditions":1653,"interventions":1655},"NCT02875886","DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease",[91],"2018-04","2016-09",[1654],"Chronic Kidney Disease",[1635,1656],"Hydrochlorothiazide",{"trials":1658,"activeCount":99},[],{"intervention":1656,"totalTrials":178,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1675},{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[],{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[1671],{"nctId":1648,"briefTitle":1649,"status":163,"phases":1672,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":810,"conditions":1673,"interventions":1674},[91],[1654],[1635,1656],{"trials":1676,"activeCount":99},[],{"intervention":1678,"totalTrials":178,"cells":1679},"Bleomycin",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1686,"PHASE4":1688,"NA":1702},{"trials":1681,"activeCount":99},[],{"trials":1683,"activeCount":99},[],{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":99},[],{"trials":1689,"activeCount":99},[1690],{"nctId":1691,"briefTitle":1692,"status":728,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1700},"NCT04582305","Bleomycin Jet Injections in Keloids",[91],"2022-11-18","2023-03-30","2022-03-18",14,[1699],"Keloid",[1678,1701],"Normal saline",{"trials":1703,"activeCount":99},[],{"intervention":1701,"totalTrials":178,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1712,"PHASE4":1714,"NA":1720},{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":99},[],{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[1716],{"nctId":1691,"briefTitle":1692,"status":728,"phases":1717,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1718,"interventions":1719},[91],[1699],[1678,1701],{"trials":1721,"activeCount":99},[],{"intervention":1723,"totalTrials":178,"cells":1724},"HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg\u002Fml",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1746},{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[1735],{"nctId":1736,"briefTitle":1737,"status":163,"phases":1738,"primaryCompletion":1739,"completion":1740,"start":1741,"enrollment":1742,"conditions":1743,"interventions":1745},"NCT00230061","Hepatitis B Vaccination in HIV-infected Persons",[91],"2008-05","2010-02","2004-04",800,[769,1744],"Hepatitis B",[1723],{"trials":1747,"activeCount":99},[],{"intervention":1749,"totalTrials":178,"cells":1750},"Dolutegravir",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1757,"PHASE4":1759,"NA":1770},{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[],{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[1761],{"nctId":1762,"briefTitle":1763,"status":163,"phases":1764,"primaryCompletion":1447,"completion":1765,"start":1766,"enrollment":1196,"conditions":1767,"interventions":1769},"NCT02401828","The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial",[91],"2017-07","2015-03",[1768],"Human Immunodeficiency Virus",[1749],{"trials":1771,"activeCount":99},[],{"intervention":1773,"totalTrials":178,"cells":1774},"2,5% lidocaine \u002F 2,5% prilocaine cream",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1796},{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[],{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[1785],{"nctId":1786,"briefTitle":1787,"status":163,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":778,"conditions":1791,"interventions":1794},"NCT02372786","7% Lidocaine\u002F7% Tetracaine Cream Versus 2,5% Lidocaine \u002F 2,5% Prilocaine Cream",[91],"2015-09","2014-11",[1792,1793],"Tattoo","Acne Keloidalis Nuchae",[1773,1795],"7% lidocaine \u002F 7% tetracaine cream",{"trials":1797,"activeCount":99},[],{"intervention":1795,"totalTrials":178,"cells":1799},{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1814},{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[1810],{"nctId":1786,"briefTitle":1787,"status":163,"phases":1811,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":778,"conditions":1812,"interventions":1813},[91],[1792,1793],[1773,1795],{"trials":1815,"activeCount":99},[],{"intervention":1817,"totalTrials":178,"cells":1818},"Preoperative conjunctival irrigation with 5% or 1.25% PI",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1827,"NA":1841},{"trials":1820,"activeCount":99},[],{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[1829],{"nctId":1830,"briefTitle":1831,"status":163,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1840},"NCT00461656","Povidone-iodine Antisepsis for Strabismus Surgery",[91],"2012-12","2009-09",70,[1837,1838,1839],"Strabismus","Surgery","Endophthalmitis",[1817],{"trials":1842,"activeCount":99},[],{"intervention":1844,"totalTrials":178,"cells":1845},"Ticagrelor",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1854,"NA":1867},{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[1856],{"nctId":1857,"briefTitle":1858,"status":163,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":1863,"interventions":1864},"NCT02587260","Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)",[91],"2017-02-10","2015-12-17",54,[336],[1844,1865,1866],"Prasugrel","Clopidogrel",{"trials":1868,"activeCount":99},[],{"intervention":1865,"totalTrials":178,"cells":1870},{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1879,"NA":1885},{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[1881],{"nctId":1857,"briefTitle":1858,"status":163,"phases":1882,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":1883,"interventions":1884},[91],[336],[1844,1865,1866],{"trials":1886,"activeCount":99},[],{"intervention":1866,"totalTrials":178,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1903},{"trials":1890,"activeCount":99},[],{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[],{"trials":1898,"activeCount":99},[1899],{"nctId":1857,"briefTitle":1858,"status":163,"phases":1900,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":1901,"interventions":1902},[91],[336],[1844,1865,1866],{"trials":1904,"activeCount":99},[],{"intervention":1906,"totalTrials":178,"cells":1907},"Tibolone",{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1930},{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[],{"trials":1917,"activeCount":99},[1918],{"nctId":1919,"briefTitle":1920,"status":163,"phases":1921,"completion":1517,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1927},"NCT00294463","Effects of Tibolone Treatment on the Endometrium",[91],"2003-02",35,[1925,1926],"Postmenopause","Osteoporosis",[1906,1928,1929],"Estradiol","Estradiol + Medroxy Progesterone Acetate",{"trials":1931,"activeCount":99},[],{"intervention":1928,"totalTrials":178,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1948},{"trials":1935,"activeCount":99},[],{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"trials":1943,"activeCount":99},[1944],{"nctId":1919,"briefTitle":1920,"status":163,"phases":1945,"completion":1517,"start":1922,"enrollment":1923,"conditions":1946,"interventions":1947},[91],[1925,1926],[1906,1928,1929],{"trials":1949,"activeCount":99},[],{"intervention":1929,"totalTrials":178,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1966},{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[1962],{"nctId":1919,"briefTitle":1920,"status":163,"phases":1963,"completion":1517,"start":1922,"enrollment":1923,"conditions":1964,"interventions":1965},[91],[1925,1926],[1906,1928,1929],{"trials":1967,"activeCount":99},[],{"intervention":1969,"totalTrials":178,"cells":1970},"Tamoxifen",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1991},{"trials":1972,"activeCount":99},[],{"trials":1974,"activeCount":99},[],{"trials":1976,"activeCount":99},[],{"trials":1978,"activeCount":99},[],{"trials":1980,"activeCount":99},[1981],{"nctId":1982,"briefTitle":1983,"status":728,"phases":1984,"primaryCompletion":1985,"completion":1986,"start":1987,"enrollment":494,"conditions":1988,"interventions":1990},"NCT05525481","Tamoxifen Prediction Study in Patients With ER+ Breast Cancer",[91],"2023-12-31","2024-02-28","2022-11-01",[1989],"ER+ Breast Cancer",[1969],{"trials":1992,"activeCount":99},[],{"intervention":1994,"totalTrials":178,"cells":1995},"Lorazepam",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2016},{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[2006],{"nctId":2007,"briefTitle":2008,"status":163,"phases":2009,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2014},"NCT01441843","Resistance Under the Microscope",[91],"2011-09","2010-10",400,[18],[1994,2015],"NaCl 0.9%",{"trials":2017,"activeCount":99},[],{"intervention":2015,"totalTrials":178,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2034},{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[],{"trials":2029,"activeCount":99},[2030],{"nctId":2007,"briefTitle":2008,"status":163,"phases":2031,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2032,"interventions":2033},[91],[18],[1994,2015],{"trials":2035,"activeCount":99},[],{"intervention":2037,"totalTrials":178,"cells":2038},"Amiloride Hcl 5mg Tab",{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2059},{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[2049],{"nctId":2050,"briefTitle":2051,"status":163,"phases":2052,"primaryCompletion":2053,"completion":2053,"start":2054,"enrollment":2055,"conditions":2056,"interventions":2058},"NCT05228574","Treatment of Vascular Stiffness in ADPKD",[91],"2025-06-18","2022-03-11",46,[2057],"Autosomal Dominant Polycystic Kidney",[2037],{"trials":2060,"activeCount":99},[],{"intervention":2062,"totalTrials":178,"cells":2063},"Esomeprazole 40mg concomitantly",{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2087},{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[2074],{"nctId":2075,"briefTitle":2076,"status":163,"phases":2077,"primaryCompletion":2078,"completion":2078,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2084},"NCT02800330","The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib",[91],"2018-02","2016-05",31,[2082,2083],"Colorectal Neoplasms","Gastrointestinal Stromal Tumors",[2062,2085,2086],"Esomeprazole 40mg before","Regorafenib 160mg or 120mg",{"trials":2088,"activeCount":99},[],{"intervention":2085,"totalTrials":178,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2105},{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[2101],{"nctId":2075,"briefTitle":2076,"status":163,"phases":2102,"primaryCompletion":2078,"completion":2078,"start":2079,"enrollment":2080,"conditions":2103,"interventions":2104},[91],[2082,2083],[2062,2085,2086],{"trials":2106,"activeCount":99},[],{"intervention":2086,"totalTrials":178,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2123},{"trials":2110,"activeCount":99},[],{"trials":2112,"activeCount":99},[],{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[2119],{"nctId":2075,"briefTitle":2076,"status":163,"phases":2120,"primaryCompletion":2078,"completion":2078,"start":2079,"enrollment":2080,"conditions":2121,"interventions":2122},[91],[2082,2083],[2062,2085,2086],{"trials":2124,"activeCount":99},[],{"intervention":497,"totalTrials":178,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2141},{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[],{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[2137],{"nctId":488,"briefTitle":489,"status":163,"phases":2138,"primaryCompletion":491,"completion":492,"start":493,"enrollment":494,"conditions":2139,"interventions":2140},[91],[483],[70,497,485],{"trials":2142,"activeCount":99},[],{"intervention":1451,"totalTrials":178,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2159},{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[2155],{"nctId":1443,"briefTitle":1444,"status":728,"phases":2156,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1349,"conditions":2157,"interventions":2158},[91],[1440],[1451,1421],{"trials":2160,"activeCount":99},[],{"intervention":2162,"totalTrials":178,"cells":2163},"Enalapril\u002Fhydrochlorothiazide",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2184},{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[],{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[2174],{"nctId":2175,"briefTitle":2176,"status":728,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":2179,"enrollment":2180,"conditions":2181,"interventions":2183},"NCT02214498","Treatment of HYpertension: Morning Versus Evening",[91],"2017-05","2015-05",120,[2182],"Essential Hypertension",[2162],{"trials":2185,"activeCount":99},[],{"intervention":2187,"totalTrials":178,"cells":2188},"tobramycin inhalation",{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2197,"NA":2208},{"trials":2190,"activeCount":99},[],{"trials":2192,"activeCount":99},[],{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[],{"trials":2198,"activeCount":99},[2199],{"nctId":2200,"briefTitle":2201,"status":163,"phases":2202,"primaryCompletion":2203,"completion":2204,"start":1766,"enrollment":743,"conditions":2205,"interventions":2207},"NCT02440828","Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia",[91],"2020-03-01","2020-07-01",[2206],"Ventilator Associated Pneumonia (VAP)",[2187],{"trials":2209,"activeCount":99},[],{"intervention":2211,"totalTrials":178,"cells":2212},"Salbutamol",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2234},{"trials":2214,"activeCount":99},[],{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[2223],{"nctId":2224,"briefTitle":2225,"status":163,"phases":2226,"primaryCompletion":2227,"completion":2227,"start":2228,"enrollment":2229,"conditions":2230,"interventions":2232},"NCT03493503","Status Asthmaticus on the PICU; Intravenous Salbutamol",[91],"2019-05-21","2017-04-05",58,[2231],"Childhood Asthma With Status Asthmaticus",[2211,2233],"Sodium Chloride 0.9%",{"trials":2235,"activeCount":99},[],{"intervention":2233,"totalTrials":178,"cells":2237},{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2244,"PHASE4":2246,"NA":2252},{"trials":2239,"activeCount":99},[],{"trials":2241,"activeCount":99},[],{"trials":2243,"activeCount":99},[],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[2248],{"nctId":2224,"briefTitle":2225,"status":163,"phases":2249,"primaryCompletion":2227,"completion":2227,"start":2228,"enrollment":2229,"conditions":2250,"interventions":2251},[91],[2231],[2211,2233],{"trials":2253,"activeCount":99},[],{"intervention":2255,"totalTrials":178,"cells":2256},"etanercept",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2277},{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[2267],{"nctId":2268,"briefTitle":2269,"status":728,"phases":2270,"primaryCompletion":2271,"completion":2272,"start":2273,"enrollment":124,"conditions":2274,"interventions":2276},"NCT01287715","Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis",[91],"2012-09","2013-09","2011-01",[2275],"Juvenile Idiopathic Arthritis",[2255,2255],{"trials":2278,"activeCount":99},[],{"intervention":2280,"totalTrials":134,"cells":2281},"tadalafil",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2307,"NA":2309},{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[2290,2299],{"nctId":2291,"briefTitle":2292,"status":163,"phases":2293,"completion":2294,"start":1922,"conditions":2295,"interventions":2298},"NCT00122499","A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer",[90],"2005-02",[2296,2297],"Prostate Cancer","Erectile Dysfunction",[2280],{"nctId":2300,"briefTitle":2301,"status":477,"phases":2302,"completion":2303,"start":2304,"enrollment":494,"conditions":2305,"interventions":2306},"NCT00215631","Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?",[90],"2005-11","2005-10",[2296,2297],[2280],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"intervention":2312,"totalTrials":134,"cells":2313},"Hyperbaric oxygen",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2344,"NA":2346},{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[],{"trials":2321,"activeCount":99},[2322,2336],{"nctId":2323,"briefTitle":2324,"status":728,"phases":2325,"primaryCompletion":976,"completion":2326,"start":415,"enrollment":2180,"conditions":2327,"interventions":2335},"NCT06267300","Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial",[90],"2026-04-01",[2328,2329,2330,2331,2332,2333,2334],"Post-COVID-19 Syndrome","Post-COVID Syndrome","Post COVID-19 Condition","Post-COVID Condition","Post COVID-19 Condition, Unspecified","Long COVID","Long Covid19",[2312],{"nctId":2337,"briefTitle":2338,"status":477,"phases":2339,"primaryCompletion":2340,"completion":2340,"start":1113,"enrollment":703,"conditions":2341,"interventions":2343},"NCT05343754","Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum",[90],"2024-01-14",[2342],"Pyoderma Gangrenosum",[2312],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":2349,"totalTrials":178,"cells":2350},"Lamotrigine",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2369,"NA":2371},{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[],{"trials":2358,"activeCount":99},[2359],{"nctId":2360,"briefTitle":2361,"status":477,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},"NCT02256124","Effect of Lamotrigine on Cognition in NF1",[89,90],"2020-04","2014-10",41,[2367],"Neurofibromatosis Type 1",[2349],{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"intervention":2374,"totalTrials":178,"cells":2375},"nebulised liposomal amphotericin B",{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2382,"PHASE4":2394,"NA":2396},{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[2384],{"nctId":2385,"briefTitle":2386,"status":163,"phases":2387,"completion":2388,"start":2389,"enrollment":2390,"conditions":2391,"interventions":2393},"NCT00263315","Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis",[89,90],"2006-05","2000-01",320,[2392],"Aspergillosis",[2374],{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[],{"intervention":2399,"totalTrials":178,"cells":2400},"switch to Myfortic",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2407,"PHASE4":2418,"NA":2420},{"trials":2402,"activeCount":99},[],{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[2409],{"nctId":2410,"briefTitle":2411,"status":477,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":1437,"enrollment":765,"conditions":2414,"interventions":2416},"NCT00504244","Myfortic Versus Azathioprine in Systemic Lupus Erythematosus",[90],"2009-08",[2415],"Systemic Lupus Erythematosus",[2399,2417],"continuation of azathioprine",{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"intervention":2417,"totalTrials":178,"cells":2423},{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2436,"NA":2438},{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[2432],{"nctId":2410,"briefTitle":2411,"status":477,"phases":2433,"primaryCompletion":2413,"completion":2413,"start":1437,"enrollment":765,"conditions":2434,"interventions":2435},[90],[2415],[2399,2417],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[],{"intervention":2441,"totalTrials":178,"cells":2442},"Subcutaneous hydromorphone delivered by pain pen",{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2449,"PHASE4":2460,"NA":2462},{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[],{"trials":2448,"activeCount":99},[],{"trials":2450,"activeCount":99},[2451],{"nctId":2452,"briefTitle":2453,"status":477,"phases":2454,"primaryCompletion":1739,"completion":1739,"start":2455,"enrollment":124,"conditions":2456,"interventions":2459},"NCT00125801","The Pain Pen for Breakthrough Cancer Pain",[90],"2005-08",[2457,2458],"Neoplasms","Pain",[2441],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"intervention":2465,"totalTrials":178,"cells":2466},"Imiquimod",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2485,"NA":2487},{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"trials":2474,"activeCount":99},[2475],{"nctId":2476,"briefTitle":2477,"status":728,"phases":2478,"primaryCompletion":2479,"completion":2480,"start":2079,"enrollment":2481,"conditions":2482,"interventions":2484},"NCT02669459","Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol",[90],"2019-03","2020-03",433,[2483],"Cervical Intraepithelial Neoplasia",[2465],{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"intervention":2490,"totalTrials":178,"cells":2491},"Everolimus",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2513,"NA":2515},{"trials":2493,"activeCount":99},[],{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[2500],{"nctId":2501,"briefTitle":2502,"status":728,"phases":2503,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":1349,"conditions":2507,"interventions":2512},"NCT01730209","Efficacy of RAD001\u002FEverolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex",[89,90],"2015-11","2016-11","2012-11",[2508,2509,2510,2511],"Tuberous Sclerosis Complex","TSC Related Cognitive Disability","TSC Related Autism","TSC Related Learning Problems",[2490],{"trials":2514,"activeCount":99},[],{"trials":2516,"activeCount":99},[],{"intervention":2518,"totalTrials":178,"cells":2519},"Convalescent plasma",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2538,"NA":2540},{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[2528],{"nctId":2529,"briefTitle":2530,"status":477,"phases":2531,"primaryCompletion":2204,"completion":2532,"start":2533,"enrollment":2534,"conditions":2535,"interventions":2537},"NCT04342182","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)",[89,90],"2020-09-30","2020-04-08",86,[2536],"COVID-19",[2518],{"trials":2539,"activeCount":99},[],{"trials":2541,"activeCount":99},[],{"intervention":2543,"totalTrials":178,"cells":2544},"Edoxaban",{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2562,"NA":2564},{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":99},[],{"trials":2552,"activeCount":99},[2553],{"nctId":2554,"briefTitle":2555,"status":728,"phases":2556,"primaryCompletion":2557,"completion":2558,"start":2559,"enrollment":494,"conditions":2560,"interventions":2561},"NCT04171726","Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation",[90],"2023-06-01","2023-09-01","2019-08-01",[24],[2543],{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[],{"intervention":2567,"totalTrials":178,"cells":2568},"ConvP",{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2589,"NA":2591},{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[2577],{"nctId":2578,"briefTitle":2579,"status":477,"phases":2580,"primaryCompletion":2581,"completion":2582,"start":2583,"enrollment":2584,"conditions":2585,"interventions":2587},"NCT04589949","Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)",[90],"2021-10-01","2022-03-01","2020-10-12",420,[2586],"Covid19",[2567,2588],"FFP",{"trials":2590,"activeCount":99},[],{"trials":2592,"activeCount":99},[],{"intervention":2588,"totalTrials":178,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2601,"PHASE4":2607,"NA":2609},{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[2603],{"nctId":2578,"briefTitle":2579,"status":477,"phases":2604,"primaryCompletion":2581,"completion":2582,"start":2583,"enrollment":2584,"conditions":2605,"interventions":2606},[90],[2586],[2567,2588],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"intervention":2612,"totalTrials":178,"cells":2613},"Pentoxifylline",{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2620,"PHASE4":2632,"NA":2634},{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[2622],{"nctId":2623,"briefTitle":2624,"status":163,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":778,"conditions":2629,"interventions":2631},"NCT04152980","Pentoxifylline Dose Optimization in Neonatal Sepsis",[90],"2022-10-31","2022-12-31","2020-01-12",[2630],"Neonatal Late Onset Sepsis",[2612],{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[],{"intervention":2637,"totalTrials":178,"cells":2638},"pregabalin",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2656,"NA":2658},{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":99},[2647],{"nctId":2648,"briefTitle":2649,"status":163,"phases":2650,"primaryCompletion":2651,"completion":2011,"start":2652,"enrollment":360,"conditions":2653,"interventions":2655},"NCT00772291","Chronic Pain Management After Herniorraphy",[90],"2010-08","2007-05",[2654],"Chronic Pain",[2637],{"trials":2657,"activeCount":99},[],{"trials":2659,"activeCount":99},[],{"intervention":2661,"totalTrials":178,"cells":2662},"Testosterone gel",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2680,"NA":2682},{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[2671],{"nctId":2672,"briefTitle":2673,"status":728,"phases":2674,"primaryCompletion":2675,"completion":2675,"start":2676,"enrollment":178,"conditions":2677,"interventions":2679},"NCT04831099","Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study",[90],"2022-07-26","2021-06-01",[2678],"Disorder of Sex Development, 46,XY",[2661],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"intervention":2685,"totalTrials":178,"cells":2686},"Formoterol-beclomethasone",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2704,"NA":2706},{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[2695],{"nctId":2696,"briefTitle":2697,"status":477,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":732,"conditions":2701,"interventions":2703},"NCT03846570","Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial",[90],"2022-07-05","2019-01-29",[2702],"Bronchiectasis",[2685],{"trials":2705,"activeCount":99},[],{"trials":2707,"activeCount":99},[],{"intervention":2709,"totalTrials":178,"cells":2710},"Chlorthalidone",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2729,"NA":2731},{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[],{"trials":2718,"activeCount":99},[2719],{"nctId":2720,"briefTitle":2721,"status":163,"phases":2722,"primaryCompletion":1861,"completion":2723,"start":2724,"enrollment":11,"conditions":2725,"interventions":2727},"NCT02644395","Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus",[90],"2016-12-19","2013-01-18",[32,2726],"Kidney Transplantation",[2709,2728],"Amlodipine",{"trials":2730,"activeCount":99},[],{"trials":2732,"activeCount":99},[],{"intervention":2728,"totalTrials":178,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[2743],{"nctId":2720,"briefTitle":2721,"status":163,"phases":2744,"primaryCompletion":1861,"completion":2723,"start":2724,"enrollment":11,"conditions":2745,"interventions":2746},[90],[32,2726],[2709,2728],{"trials":2748,"activeCount":99},[],{"trials":2750,"activeCount":99},[],{"intervention":2752,"totalTrials":178,"cells":2753},"Grazoprevir\u002FElbasvir 100mg\u002F50mg",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2773,"NA":2775},{"trials":2755,"activeCount":99},[],{"trials":2757,"activeCount":99},[],{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[2762],{"nctId":2763,"briefTitle":2764,"status":163,"phases":2765,"primaryCompletion":2766,"completion":2767,"start":2768,"enrollment":743,"conditions":2769,"interventions":2772},"NCT02600325","Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir\u002FElbasvir for Acute HCV",[90],"2018-04-01","2019-01-11","2016-02",[2770,1768,2771],"Acute Hepatitis C","Hepatitis C",[2752],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"intervention":2778,"totalTrials":178,"cells":2779},"Haloperidol",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2786,"PHASE4":2803,"NA":2805},{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[2788],{"nctId":2789,"briefTitle":2790,"status":477,"phases":2791,"primaryCompletion":2792,"completion":2793,"start":2794,"enrollment":2795,"conditions":2796,"interventions":2802},"NCT03628391","Haloperidol for Delirium in Adult Critically Ill Patients",[90],"2020-02-03","2021-01-23","2018-02-22",142,[2797,2798,2799,2800,2801],"Delirium","Critical Illness","Intensive Care Psychosis","Cognitive Impairment","Cognitive Decline",[2778],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"intervention":2808,"totalTrials":178,"cells":2809},"Azole",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2816,"PHASE4":2828,"NA":2830},{"trials":2811,"activeCount":99},[],{"trials":2813,"activeCount":99},[],{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[2818],{"nctId":2819,"briefTitle":2820,"status":477,"phases":2821,"primaryCompletion":2822,"completion":2822,"start":2823,"enrollment":951,"conditions":2824,"interventions":2826},"NCT04876716","Azole-echinocandin Combination Therapy for Invasive Aspergillosis",[90],"2024-05-01","2021-05-11",[2825],"Invasive Aspergillosis",[2808,2827],"Anidulafungin",{"trials":2829,"activeCount":99},[],{"trials":2831,"activeCount":99},[],{"intervention":2827,"totalTrials":178,"cells":2833},{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2838,"PHASE3":2840,"PHASE4":2846,"NA":2848},{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":99},[],{"trials":2839,"activeCount":99},[],{"trials":2841,"activeCount":99},[2842],{"nctId":2819,"briefTitle":2820,"status":477,"phases":2843,"primaryCompletion":2822,"completion":2822,"start":2823,"enrollment":951,"conditions":2844,"interventions":2845},[90],[2825],[2808,2827],{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"intervention":2851,"totalTrials":178,"cells":2852},"Hydrocortisone",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2859,"PHASE4":2869,"NA":2871},{"trials":2854,"activeCount":99},[],{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[2861],{"nctId":2862,"briefTitle":2863,"status":728,"phases":2864,"primaryCompletion":2865,"completion":2865,"start":2676,"enrollment":178,"conditions":2866,"interventions":2868},"NCT04821583","Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study",[90],"2022-09-01",[2867],"Symmetric Lipomatoses, Multiple",[2851],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[],{"intervention":2874,"totalTrials":134,"cells":2875},"cabazitaxel",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[],{"trials":2881,"activeCount":99},[2882,2892],{"nctId":2883,"briefTitle":2884,"status":2885,"phases":2886,"primaryCompletion":2887,"completion":2888,"start":2768,"enrollment":99,"conditions":2889,"interventions":2891},"NCT02621190","Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs","WITHDRAWN",[89],"2019-02","2019-06",[2890],"Prostatic Neoplasms",[2874],{"nctId":2893,"briefTitle":2894,"status":728,"phases":2895,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":360,"conditions":2899,"interventions":2902},"NCT03050866","Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)",[89],"2022-01-01","2022-08-19","2017-02-21",[2900,2901],"Circulating Tumor Cell","Metastatic Prostate Cancer",[2903],"Cabazitaxel",{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"intervention":2911,"totalTrials":178,"cells":2912},"Intraperitoneal Paclitaxel Solution",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2914,"activeCount":99},[],{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[2919],{"nctId":2920,"briefTitle":2921,"status":163,"phases":2922,"primaryCompletion":864,"completion":2923,"start":2924,"enrollment":25,"conditions":2925,"interventions":2927},"NCT05449366","Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma",[88,89],"2025-08-01","2022-02-01",[2926],"Peritoneal Malignant Mesothelioma",[2911],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"intervention":2935,"totalTrials":178,"cells":2936},"Boceprevir",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2952,"PHASE4":2954,"NA":2956},{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[2943],{"nctId":2944,"briefTitle":2945,"status":163,"phases":2946,"primaryCompletion":1448,"completion":2947,"start":2948,"enrollment":2949,"conditions":2950,"interventions":2951},"NCT01912495","Dutch Acute HCV in HIV Study (DAHHS)",[89],"2016-01","2013-08",65,[2771,1768],[2935],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[],{"intervention":2959,"totalTrials":178,"cells":2960},"Pembrolizumab",{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2977,"PHASE4":2979,"NA":2981},{"trials":2962,"activeCount":99},[],{"trials":2964,"activeCount":99},[],{"trials":2966,"activeCount":99},[2967],{"nctId":2968,"briefTitle":2969,"status":728,"phases":2970,"primaryCompletion":2897,"completion":2971,"start":2972,"enrollment":743,"conditions":2973,"interventions":2976},"NCT03263039","Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab",[89],"2023-08-19","2017-08-21",[2974,2975],"Transitional Cell Carcinoma of the Bladder","Biomarkers",[2959],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[],{"trials":2982,"activeCount":99},[],{"intervention":2984,"totalTrials":178,"cells":2985},"ISA104",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":3001,"PHASE4":3003,"NA":3005},{"trials":2987,"activeCount":99},[],{"trials":2989,"activeCount":99},[],{"trials":2991,"activeCount":99},[2992],{"nctId":2993,"briefTitle":2994,"status":728,"phases":2995,"primaryCompletion":2996,"completion":79,"start":2997,"enrollment":1114,"conditions":2998,"interventions":3000},"NCT05841095","Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104",[88,89],"2024-09-01","2023-08-04",[2999],"Chronic Hepatitis b",[2984],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":99},[],{"trials":3006,"activeCount":99},[],{"intervention":3008,"totalTrials":178,"cells":3009},"delta-24-RGD adenovirus",{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3011,"activeCount":99},[],{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[3016],{"nctId":3017,"briefTitle":3018,"status":163,"phases":3019,"primaryCompletion":479,"completion":479,"start":3020,"enrollment":888,"conditions":3021,"interventions":3024},"NCT01582516","Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma",[88,89],"2010-06",[3022,3023],"Brain Tumor","Recurring Glioblastoma",[3008],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"intervention":3032,"totalTrials":178,"cells":3033},"Tusamitamab ravtansine",{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3050,"PHASE4":3052,"NA":3054},{"trials":3035,"activeCount":99},[],{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[3040],{"nctId":3041,"briefTitle":3042,"status":2885,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":3044,"enrollment":99,"conditions":3045,"interventions":3049},"NCT05703555","INTRUSION: Unraveling the INTRatUmoral PK\u002FPD relatION for SAR408701",[89],"2024-02-16",[3046,3047,3048],"Metastatic Lung Cancer","Metastatic Breast Cancer","Metastatic Gastric Cancer",[3032],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[],{"intervention":3057,"totalTrials":178,"cells":3058},"TEIPP24",{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3060,"activeCount":99},[],{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[3065],{"nctId":3066,"briefTitle":3067,"status":163,"phases":3068,"primaryCompletion":3069,"completion":3069,"start":3070,"enrollment":3071,"conditions":3072,"interventions":3074},"NCT05898763","TEIPP Immunotherapy in Patients With NSCLC",[88,89],"2024-04-30","2021-09-29",26,[3073],"Non Small Cell Lung Cancer",[3057],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[],{"trials":3080,"activeCount":99},[],{"intervention":3082,"totalTrials":178,"cells":3083},"mutant pro-urokinase",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[3090],{"nctId":3091,"briefTitle":3092,"status":163,"phases":3093,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":1220,"conditions":3097,"interventions":3099},"NCT04256473","Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke",[89],"2022-03-26","2022-05-26","2019-08-10",[3098],"Ischemic Stroke",[3082,3100],"Alteplase",{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"intervention":3100,"totalTrials":178,"cells":3108},{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3113,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[],{"trials":3114,"activeCount":99},[3115],{"nctId":3091,"briefTitle":3092,"status":163,"phases":3116,"primaryCompletion":3094,"completion":3095,"start":3096,"enrollment":1220,"conditions":3117,"interventions":3118},[89],[3098],[3082,3100],{"trials":3120,"activeCount":99},[],{"trials":3122,"activeCount":99},[],{"trials":3124,"activeCount":99},[],{"intervention":3126,"totalTrials":178,"cells":3127},"Triac",{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3132,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3129,"activeCount":99},[],{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[3134],{"nctId":3135,"briefTitle":3136,"status":163,"phases":3137,"primaryCompletion":3138,"completion":3138,"start":2364,"enrollment":2055,"conditions":3139,"interventions":3141},"NCT02060474","Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients",[89],"2018-06-26",[3140],"Allan-Herndon-Dudley Syndrome",[3126],{"trials":3143,"activeCount":99},[],{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"intervention":3149,"totalTrials":178,"cells":3150},"Capecitabine",{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3169,"PHASE4":3171,"NA":3173},{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[],{"trials":3156,"activeCount":99},[3157],{"nctId":3158,"briefTitle":3159,"status":477,"phases":3160,"primaryCompletion":3161,"completion":3162,"start":3163,"enrollment":3164,"conditions":3165,"interventions":3167},"NCT07012330","Comparing 177Lu-Dotatate\u002FCapecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients",[89],"2013-12-31","2015-12-31","2007-03-01",111,[3166],"Neuroendocrine (NE) Tumors",[3149,3168],"177Lu-DOTATATE",{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"intervention":3168,"totalTrials":178,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":99},[],{"trials":3182,"activeCount":99},[3183],{"nctId":3158,"briefTitle":3159,"status":477,"phases":3184,"primaryCompletion":3161,"completion":3162,"start":3163,"enrollment":3164,"conditions":3185,"interventions":3186},[89],[3166],[3149,3168],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[],{"trials":3192,"activeCount":99},[],{"intervention":3194,"totalTrials":178,"cells":3195},"Panobinostat 20 MG Oral",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3212,"PHASE4":3214,"NA":3216},{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[3202],{"nctId":3203,"briefTitle":3204,"status":728,"phases":3205,"primaryCompletion":3206,"completion":74,"start":3207,"enrollment":11,"conditions":3208,"interventions":3209},"NCT06240520","Optimizing Reversal of HIV Latency With Combination Therapy",[88,89],"2025-05","2024-04",[768],[3194,3210,3211],"Pyrimethamine 200mg Oral","Lenalidomide 25 MG Oral",{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[],{"trials":3217,"activeCount":99},[],{"intervention":3210,"totalTrials":178,"cells":3219},{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3224,"PHASE3":3230,"PHASE4":3232,"NA":3234},{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[],{"trials":3225,"activeCount":99},[3226],{"nctId":3203,"briefTitle":3204,"status":728,"phases":3227,"primaryCompletion":3206,"completion":74,"start":3207,"enrollment":11,"conditions":3228,"interventions":3229},[88,89],[768],[3194,3210,3211],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[],{"trials":3235,"activeCount":99},[],{"intervention":3211,"totalTrials":178,"cells":3237},{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3239,"activeCount":99},[],{"trials":3241,"activeCount":99},[],{"trials":3243,"activeCount":99},[3244],{"nctId":3203,"briefTitle":3204,"status":728,"phases":3245,"primaryCompletion":3206,"completion":74,"start":3207,"enrollment":11,"conditions":3246,"interventions":3247},[88,89],[768],[3194,3210,3211],{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"intervention":813,"totalTrials":178,"cells":3255},{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3266,"PHASE4":3268,"NA":3270},{"trials":3257,"activeCount":99},[],{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[3262],{"nctId":804,"briefTitle":805,"status":163,"phases":3263,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":3264,"interventions":3265},[88,89],[767],[813,783],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":99},[],{"trials":3271,"activeCount":99},[],{"intervention":3273,"totalTrials":178,"cells":3274},"tumor lysate-loaded autologous dendritic cells",{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3293},{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[3279],{"nctId":3280,"briefTitle":3281,"status":163,"phases":3282,"primaryCompletion":1834,"completion":1834,"start":3283,"enrollment":416,"conditions":3284,"interventions":3286},"NCT00280982","Dendritic Cell-based Immunotherapy in Mesothelioma",[88],"2006-01",[3285],"Malignant Pleural Mesothelioma",[3273],{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"trials":3294,"activeCount":99},[],{"intervention":3296,"totalTrials":178,"cells":3297},"Propofol",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3315,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[3302],{"nctId":3303,"briefTitle":3304,"status":477,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":3308,"conditions":3309,"interventions":3314},"NCT02040909","Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation",[88],"2018-01-23","2014-07",91,[3310,3311,3312,3313],"Anesthesia Intubation Complication","Premature Birth of Newborn","Other Preterm Infants","Propofol Overdose",[3296],{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":99},[],{"trials":3320,"activeCount":99},[],{"trials":3322,"activeCount":99},[],{"intervention":3324,"totalTrials":178,"cells":3325},"MesoCancerVac",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[3330],{"nctId":3331,"briefTitle":3332,"status":728,"phases":3333,"primaryCompletion":3334,"completion":1607,"start":3335,"enrollment":19,"conditions":3336,"interventions":3338},"NCT02395679","Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients",[88],"2015-12","2015-01",[3337],"Mesothelioma",[3324],{"trials":3340,"activeCount":99},[],{"trials":3342,"activeCount":99},[],{"trials":3344,"activeCount":99},[],{"trials":3346,"activeCount":99},[],{"intervention":3348,"totalTrials":178,"cells":3349},"DC + CTX",{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[3354],{"nctId":3355,"briefTitle":3356,"status":163,"phases":3357,"primaryCompletion":3358,"completion":3359,"start":3360,"enrollment":416,"conditions":3361,"interventions":3363},"NCT01241682","Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma",[88],"2011-10","2012-10","2009-10",[3362],"Malignant (Pleural) Mesothelioma",[3348],{"trials":3365,"activeCount":99},[],{"trials":3367,"activeCount":99},[],{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":99},[],{"intervention":3373,"totalTrials":178,"cells":3374},"Irinotecan",{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3376,"activeCount":99},[],{"trials":3378,"activeCount":99},[3379],{"nctId":3380,"briefTitle":3381,"status":163,"phases":3382,"primaryCompletion":3383,"completion":3384,"start":3385,"enrollment":888,"conditions":3386,"interventions":3389},"NCT05379790","Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin",[88],"2024-11-25","2025-02-17","2022-05-25",[3387,3388],"Gastric Cancer","Peritoneal Metastases",[3373,3390],"CAPOX",{"trials":3392,"activeCount":99},[],{"trials":3394,"activeCount":99},[],{"trials":3396,"activeCount":99},[],{"trials":3398,"activeCount":99},[],{"intervention":3390,"totalTrials":178,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3409,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[3405],{"nctId":3380,"briefTitle":3381,"status":163,"phases":3406,"primaryCompletion":3383,"completion":3384,"start":3385,"enrollment":888,"conditions":3407,"interventions":3408},[88],[3387,3388],[3373,3390],{"trials":3410,"activeCount":99},[],{"trials":3412,"activeCount":99},[],{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[],{"intervention":518,"totalTrials":134,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3439},{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[],{"trials":3428,"activeCount":99},[3429],{"nctId":3430,"briefTitle":3431,"status":728,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":3435,"conditions":3436,"interventions":3438},"NCT03221621","Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS",[91],"2022-07-31","2018-07-31",128,[3437],"Hidradenitis Suppurativa",[518],{"trials":3440,"activeCount":99},[3441],{"nctId":509,"briefTitle":510,"status":163,"phases":3442,"primaryCompletion":512,"completion":513,"start":514,"enrollment":220,"conditions":3443,"interventions":3444},[],[516],[70,518],{"intervention":3446,"totalTrials":178,"cells":3447},"Sirolimus",{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3449,"activeCount":99},[],{"trials":3451,"activeCount":99},[],{"trials":3453,"activeCount":99},[],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"trials":3459,"activeCount":99},[3460],{"nctId":3461,"briefTitle":3462,"status":477,"phases":3463,"primaryCompletion":2947,"completion":1607,"start":3307,"enrollment":3464,"conditions":3465,"interventions":3467},"NCT02214706","Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus",[92],17,[3466],"Port-Wine Stain",[3446],{"intervention":3469,"totalTrials":178,"cells":3470},"Direct boost mRNA",{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3472,"activeCount":99},[],{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[3483],{"nctId":3484,"briefTitle":3485,"status":728,"phases":3486,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":3490,"conditions":3491,"interventions":3493},"NCT05471440","SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW",[92],"2022-09-15","2023-08-30","2022-08-20",431,[3492],"Covid-19 Vaccination",[3469,3494,3495,3496],"Direct boost adeno","Post-poned boost mRNA","Post-poned boost adeno",{"intervention":3494,"totalTrials":178,"cells":3498},{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3500,"activeCount":99},[],{"trials":3502,"activeCount":99},[],{"trials":3504,"activeCount":99},[],{"trials":3506,"activeCount":99},[],{"trials":3508,"activeCount":99},[],{"trials":3510,"activeCount":99},[3511],{"nctId":3484,"briefTitle":3485,"status":728,"phases":3512,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":3490,"conditions":3513,"interventions":3514},[92],[3492],[3469,3494,3495,3496],{"intervention":3495,"totalTrials":178,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3518,"activeCount":99},[],{"trials":3520,"activeCount":99},[],{"trials":3522,"activeCount":99},[],{"trials":3524,"activeCount":99},[],{"trials":3526,"activeCount":99},[],{"trials":3528,"activeCount":99},[3529],{"nctId":3484,"briefTitle":3485,"status":728,"phases":3530,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":3490,"conditions":3531,"interventions":3532},[92],[3492],[3469,3494,3495,3496],{"intervention":3496,"totalTrials":178,"cells":3534},{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3536,"activeCount":99},[],{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[],{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[3547],{"nctId":3484,"briefTitle":3485,"status":728,"phases":3548,"primaryCompletion":3487,"completion":3488,"start":3489,"enrollment":3490,"conditions":3549,"interventions":3550},[92],[3492],[3469,3494,3495,3496],{"intervention":3552,"totalTrials":178,"cells":3553},"eplerenone",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3555,"activeCount":99},[],{"trials":3557,"activeCount":99},[],{"trials":3559,"activeCount":99},[],{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[3566],{"nctId":3567,"briefTitle":3568,"status":728,"phases":3569,"completion":3570,"start":3571,"enrollment":197,"conditions":3572,"interventions":3574},"NCT00407784","Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.",[],"2009-11","2007-01",[3573,32],"Hyperaldosteronism",[3552],{"intervention":3576,"totalTrials":178,"cells":3577},"Standard lifestyle recommendations + dietary supplementation",{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3579,"activeCount":99},[],{"trials":3581,"activeCount":99},[],{"trials":3583,"activeCount":99},[],{"trials":3585,"activeCount":99},[],{"trials":3587,"activeCount":99},[],{"trials":3589,"activeCount":99},[3590],{"nctId":3591,"briefTitle":3592,"status":163,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":3596,"conditions":3597,"interventions":3599},"NCT05667441","Adherence to Lifestyle Changes for Age-related Macular Degeneration",[92],"2025-07-14","2021-08-01",150,[3598],"Age-Related Macular Degeneration",[3576,3600],"Risk profiling",{"intervention":3600,"totalTrials":178,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3604,"activeCount":99},[],{"trials":3606,"activeCount":99},[],{"trials":3608,"activeCount":99},[],{"trials":3610,"activeCount":99},[],{"trials":3612,"activeCount":99},[],{"trials":3614,"activeCount":99},[3615],{"nctId":3591,"briefTitle":3592,"status":163,"phases":3616,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":3596,"conditions":3617,"interventions":3618},[92],[3598],[3576,3600],{"intervention":3620,"totalTrials":178,"cells":3621},"vena punction",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3623,"activeCount":99},[],{"trials":3625,"activeCount":99},[],{"trials":3627,"activeCount":99},[],{"trials":3629,"activeCount":99},[],{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[3634],{"nctId":3635,"briefTitle":3636,"status":163,"phases":3637,"primaryCompletion":491,"completion":3638,"start":479,"enrollment":3639,"conditions":3640,"interventions":3643},"NCT02802475","Antibodies Causing Epilepsy Syndromes: The ACES Study.",[],"2020-12",582,[3641,3642],"Auto-immune Encephalitis","Epilepsy",[3620],{"intervention":3645,"totalTrials":178,"cells":3646},"paracetamol",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"trials":3652,"activeCount":99},[],{"trials":3654,"activeCount":99},[],{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[3659],{"nctId":3660,"briefTitle":3661,"status":163,"phases":3662,"primaryCompletion":3663,"completion":3664,"start":3665,"enrollment":3666,"conditions":3667,"interventions":3670},"NCT05853263","Morphine IV vs Paracetamol IV in Neonates and Infants After Cardiac Surgery",[92],"2020-07-11","2020-07-20","2016-03-09",208,[3668,3669,1838],"Analgesia","Congenital Heart Disease",[3645,3671],"Morphine",{"intervention":3671,"totalTrials":178,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[],{"trials":3683,"activeCount":99},[],{"trials":3685,"activeCount":99},[3686],{"nctId":3660,"briefTitle":3661,"status":163,"phases":3687,"primaryCompletion":3663,"completion":3664,"start":3665,"enrollment":3666,"conditions":3688,"interventions":3689},[92],[3668,3669,1838],[3645,3671],{"intervention":3691,"totalTrials":178,"cells":3692},"Lutathera",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3699,"PHASE4":3701,"NA":3703},{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[],{"trials":3700,"activeCount":99},[],{"trials":3702,"activeCount":99},[],{"trials":3704,"activeCount":99},[3705],{"nctId":3706,"briefTitle":3707,"status":728,"phases":3708,"primaryCompletion":415,"completion":415,"start":3709,"enrollment":888,"conditions":3710,"interventions":3711},"NCT05513469","Biomarker Identification of Radionuclide Therapy-induced Radiation Responses",[92],"2023-01-01",[1116],[3691],{"intervention":3713,"totalTrials":178,"cells":3714},"Clindamycin 1 % Topical Lotion",{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3716,"activeCount":99},[],{"trials":3718,"activeCount":99},[],{"trials":3720,"activeCount":99},[],{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[],{"trials":3726,"activeCount":99},[3727],{"nctId":3728,"briefTitle":3729,"status":728,"phases":3730,"primaryCompletion":3731,"completion":777,"start":3732,"enrollment":2229,"conditions":3733,"interventions":3735},"NCT05762484","Efficacy of Laser Hair Removal Therapy in HS",[92],"2024-12","2023-04",[3734],"Hidradenitis Suppurativa, Acne Inversa",[3713],{"intervention":3737,"totalTrials":178,"cells":3738},"Cetirizine",{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[],{"trials":3746,"activeCount":99},[],{"trials":3748,"activeCount":99},[],{"trials":3750,"activeCount":99},[3751],{"nctId":3752,"briefTitle":3753,"status":163,"phases":3754,"primaryCompletion":3755,"completion":3756,"start":1113,"enrollment":3757,"conditions":3758,"interventions":3760},"NCT06039137","The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment",[],"2023-04-27","2023-10-31",395,[3759],"Solid Tumor",[3737,3761],"Clemastine IV",{"intervention":3761,"totalTrials":178,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[],{"trials":3773,"activeCount":99},[],{"trials":3775,"activeCount":99},[3776],{"nctId":3752,"briefTitle":3753,"status":163,"phases":3777,"primaryCompletion":3755,"completion":3756,"start":1113,"enrollment":3757,"conditions":3778,"interventions":3779},[],[3759],[3737,3761],{"intervention":174,"totalTrials":178,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3783,"activeCount":99},[],{"trials":3785,"activeCount":99},[],{"trials":3787,"activeCount":99},[],{"trials":3789,"activeCount":99},[],{"trials":3791,"activeCount":99},[],{"trials":3793,"activeCount":99},[3794],{"nctId":161,"briefTitle":162,"status":163,"phases":3795,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":3796,"interventions":3797},[],[147,158,169,146,170,171,172],[149,50,174,175],{"intervention":175,"totalTrials":178,"cells":3799},{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[],{"trials":3807,"activeCount":99},[],{"trials":3809,"activeCount":99},[],{"trials":3811,"activeCount":99},[3812],{"nctId":161,"briefTitle":162,"status":163,"phases":3813,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":3814,"interventions":3815},[],[147,158,169,146,170,171,172],[149,50,174,175],{"intervention":3817,"totalTrials":178,"cells":3818},"Topical corticosteroids",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3825,"PHASE4":3827,"NA":3829},{"trials":3820,"activeCount":99},[],{"trials":3822,"activeCount":99},[],{"trials":3824,"activeCount":99},[],{"trials":3826,"activeCount":99},[],{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[3831],{"nctId":3832,"briefTitle":3833,"status":728,"phases":3834,"primaryCompletion":3835,"completion":3836,"start":3837,"enrollment":3838,"conditions":3839,"interventions":3841},"NCT04878770","NMF-CsA-Dupi Trial",[92],"2024-01-01","2025-01-01","2021-08-16",318,[3840],"Dermatitis, Atopic",[3817,3842,3843],"Systemic cyclosporine","Systemic dupilumab",{"intervention":3842,"totalTrials":178,"cells":3845},{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3847,"activeCount":99},[],{"trials":3849,"activeCount":99},[],{"trials":3851,"activeCount":99},[],{"trials":3853,"activeCount":99},[],{"trials":3855,"activeCount":99},[],{"trials":3857,"activeCount":99},[3858],{"nctId":3832,"briefTitle":3833,"status":728,"phases":3859,"primaryCompletion":3835,"completion":3836,"start":3837,"enrollment":3838,"conditions":3860,"interventions":3861},[92],[3840],[3817,3842,3843],{"intervention":3843,"totalTrials":178,"cells":3863},{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3865,"activeCount":99},[],{"trials":3867,"activeCount":99},[],{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[3876],{"nctId":3832,"briefTitle":3833,"status":728,"phases":3877,"primaryCompletion":3835,"completion":3836,"start":3837,"enrollment":3838,"conditions":3878,"interventions":3879},[92],[3840],[3817,3842,3843],{"intervention":3881,"totalTrials":178,"cells":3882},"Nitroglycerin",{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":99},[],{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[],{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[3895],{"nctId":3896,"briefTitle":3897,"status":163,"phases":3898,"completion":3899,"start":3900,"enrollment":3901,"conditions":3902,"interventions":3905},"NCT00335010","Intravenous NTG to Preserve Gastric Microcirculation During Gastric Tube Reconstruction",[92],"2005-12","2005-05",32,[3903,3904],"Esophageal Neoplasms","Microcirculation",[3881],{"intervention":3907,"totalTrials":178,"cells":3908},"Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA",{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[],{"trials":3916,"activeCount":99},[],{"trials":3918,"activeCount":99},[],{"trials":3920,"activeCount":99},[3921],{"nctId":3922,"briefTitle":3923,"status":163,"phases":3924,"primaryCompletion":3925,"completion":3595,"start":3926,"enrollment":888,"conditions":3927,"interventions":3929},"NCT06022588","Chronic Mesenteric Ischemia Breath Testing",[92],"2021-04-01","2021-03-01",[3928],"Chronic Mesenteric Ischemia",[3907,3930],"U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA",{"intervention":3930,"totalTrials":178,"cells":3932},{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3943},{"trials":3934,"activeCount":99},[],{"trials":3936,"activeCount":99},[],{"trials":3938,"activeCount":99},[],{"trials":3940,"activeCount":99},[],{"trials":3942,"activeCount":99},[],{"trials":3944,"activeCount":99},[3945],{"nctId":3922,"briefTitle":3923,"status":163,"phases":3946,"primaryCompletion":3925,"completion":3595,"start":3926,"enrollment":888,"conditions":3947,"interventions":3948},[92],[3928],[3907,3930],{"intervention":3950,"totalTrials":178,"cells":3951},"Vaccination once with Janssen vaccine",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3962},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[3964],{"nctId":3965,"briefTitle":3966,"status":728,"phases":3967,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":3970,"conditions":3971,"interventions":3972},"NCT04927936","A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial",[92],"2022-09","2021-06-25",432,[2586],[3950,3973,3974,3975],"Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).","Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).","Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).",{"intervention":3973,"totalTrials":178,"cells":3977},{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3979,"activeCount":99},[],{"trials":3981,"activeCount":99},[],{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[3990],{"nctId":3965,"briefTitle":3966,"status":728,"phases":3991,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":3970,"conditions":3992,"interventions":3993},[92],[2586],[3950,3973,3974,3975],{"intervention":3974,"totalTrials":178,"cells":3995},{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[4008],{"nctId":3965,"briefTitle":3966,"status":728,"phases":4009,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":3970,"conditions":4010,"interventions":4011},[92],[2586],[3950,3973,3974,3975],{"intervention":3975,"totalTrials":178,"cells":4013},{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4015,"activeCount":99},[],{"trials":4017,"activeCount":99},[],{"trials":4019,"activeCount":99},[],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"trials":4025,"activeCount":99},[4026],{"nctId":3965,"briefTitle":3966,"status":728,"phases":4027,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":3970,"conditions":4028,"interventions":4029},[92],[2586],[3950,3973,3974,3975],{"intervention":4031,"totalTrials":178,"cells":4032},"Single target immunomodulation",{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4039,"PHASE4":4041,"NA":4043},{"trials":4034,"activeCount":99},[],{"trials":4036,"activeCount":99},[],{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[],{"trials":4042,"activeCount":99},[],{"trials":4044,"activeCount":99},[4045],{"nctId":4046,"briefTitle":4047,"status":163,"phases":4048,"primaryCompletion":2924,"completion":2924,"start":4049,"enrollment":4050,"conditions":4051,"interventions":4053},"NCT06311448","Personalized Targeted Immunomodulation in COVID-19 ARDS",[],"2020-03-02",164,[4052],"COVID-19 Acute Respiratory Distress Syndrome",[4031,4054],"Standard of care",{"intervention":4054,"totalTrials":178,"cells":4056},{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4061,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4058,"activeCount":99},[],{"trials":4060,"activeCount":99},[],{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[],{"trials":4066,"activeCount":99},[],{"trials":4068,"activeCount":99},[4069],{"nctId":4046,"briefTitle":4047,"status":163,"phases":4070,"primaryCompletion":2924,"completion":2924,"start":4049,"enrollment":4050,"conditions":4071,"interventions":4072},[],[4052],[4031,4054]]